Better Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTTX research report →
About the company
Better Therapeutics, Inc. , a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes.
- CEO
- Craig R. Jalbert
- IPO
- 2021
- Employees
- 54
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $5.45K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -221.99%
- ROIC
- -273.67%
- Revenue
- $0 · 0.00%
- Net Income
- $-39,760,000 · 1.43%
- EPS
- $-1.69 · 1.17%
- Op Income
- $-38,262,000
- FCF YoY
- 5.58%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -40.01
- Avg Volume
- 5.26K
Get TickerSpark's AI analysis on BTTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 24 | PERRY DAVID P | other | 839,895 |
| Jan 9, 24 | PERRY DAVID P | other | 1,471,453 |
| Dec 18, 23 | PERRY DAVID P | other | 3,750 |
| Dec 18, 23 | Carmona Richard H | other | 3,750 |
| Dec 18, 23 | LAVIZZO-MOUREY RISA J | other | 3,750 |
| Dec 18, 23 | Wynholds Kristin | other | 25,362 |
| Dec 18, 23 | Parker Geoffrey M. | other | 3,750 |
| Dec 18, 23 | Armanino Andrew J. | other | 3,750 |
| Dec 18, 23 | Miller Leslie A. | other | 3,587 |
| Dec 18, 23 | Granger Elder | other | 3,750 |
Our BTTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BTTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.